Trial Profile
Phase II trial of MPP-formulated loteprednol etabonate ophthalmic nanosuspension (0.25% LE-MPP) for blepharitis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Loteprednol etabonate (Primary)
- Indications Blepharitis
- Focus Therapeutic Use
- Sponsors KALA BIO
- 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO
- 08 Jan 2014 New trial record